News
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
The National Cancer Institute (NCI) is seeking a collaboration partner for a COVID-19 therapeutic that will stop the infected cells from replicating inside a host. When SARS-CoV-2 enters a host, the cells replicate it and viral particles invade the nearby healthy cells. This happens because SARS-CoV
Louis Staudt, M.D., Ph.D. was recently awarded the Career Achievement Award, which recognizes ten or more years in HHS and dedication and loyalty to the Department. Dr. Staudt is the Chief of the Lymphoid Malignancies Branch at NCI. Dr. Staudt pioneered the use of gene expression profiling to
The National Institute of Dental and Craniofacial Research (NIDCR) at the NIH has a great non-exclusive license opportunity available to commercialize a novel adeno-associated virus termed “44-9” (AAV44-9) vector for gene therapy. AAV44-9 based vectors have high gene transfer activity in many cell